The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review

Takehiro Iwata, Shoji Kimura, Mohammad Abufaraj, Florian Janisch, Pierre I. Karakiewicz, Veronika Seebacher, Morgan Rouprêt, Yasutomo Nasu, Shahrokh F. Shariat

Research output: Contribution to journalReview article

Abstract

Objectives: The role of adjuvant radiotherapy (ART) in patients with bladder cancer (BCa) and upper tract urothelial carcinoma (UTUC) is controversial. We systematically evaluated the oncologic efficacy of ART and its associated toxicity in patients treated with surgery and ART for BCa and UTUC. Materials and method: We performed a literature search on December 2018 using MEDLINE, Web of Science, Cochrane databases and Scopus according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Fourteen BCa studies and 14 UTUC studies were included in this systematic review. The data were too scarce and heterogeneous for meta-analytical analysis. Results: The quality and quantity of the data on ART in BCa and UTUC patients are limited. The combination of ART and chemotherapy appears to be beneficial in patients with locally advanced BCa or UTUC. The early and late adverse effects of ART are decreasing reflecting the progress in radiation technology. Conclusions: According to the currently available literature, there is no clear benefit of ART after radical surgery in BCa and UTUC. Future efforts should focus on evaluating multimodal approach using ART with chemotherapy. Until that time comes, ART should be used carefully in patients with BCa and UTUC on a case-by-case basis.

Original languageEnglish
JournalUrologic Oncology: Seminars and Original Investigations
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Adjuvant Radiotherapy
Urinary Tract
Urinary Bladder Neoplasms
Carcinoma
Meta-Analysis
Adjuvant Chemotherapy
MEDLINE
Databases
Radiation
Technology
Drug Therapy

Keywords

  • Adjuvant radiotherapy
  • Bladder cancer
  • Recurrence
  • Upper tract urothelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma : A systematic review. / Iwata, Takehiro; Kimura, Shoji; Abufaraj, Mohammad; Janisch, Florian; Karakiewicz, Pierre I.; Seebacher, Veronika; Rouprêt, Morgan; Nasu, Yasutomo; Shariat, Shahrokh F.

In: Urologic Oncology: Seminars and Original Investigations, 01.01.2019.

Research output: Contribution to journalReview article

Iwata, Takehiro ; Kimura, Shoji ; Abufaraj, Mohammad ; Janisch, Florian ; Karakiewicz, Pierre I. ; Seebacher, Veronika ; Rouprêt, Morgan ; Nasu, Yasutomo ; Shariat, Shahrokh F. / The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma : A systematic review. In: Urologic Oncology: Seminars and Original Investigations. 2019.
@article{29fcac1eb2904cf19f69ae912e35e964,
title = "The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review",
abstract = "Objectives: The role of adjuvant radiotherapy (ART) in patients with bladder cancer (BCa) and upper tract urothelial carcinoma (UTUC) is controversial. We systematically evaluated the oncologic efficacy of ART and its associated toxicity in patients treated with surgery and ART for BCa and UTUC. Materials and method: We performed a literature search on December 2018 using MEDLINE, Web of Science, Cochrane databases and Scopus according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Fourteen BCa studies and 14 UTUC studies were included in this systematic review. The data were too scarce and heterogeneous for meta-analytical analysis. Results: The quality and quantity of the data on ART in BCa and UTUC patients are limited. The combination of ART and chemotherapy appears to be beneficial in patients with locally advanced BCa or UTUC. The early and late adverse effects of ART are decreasing reflecting the progress in radiation technology. Conclusions: According to the currently available literature, there is no clear benefit of ART after radical surgery in BCa and UTUC. Future efforts should focus on evaluating multimodal approach using ART with chemotherapy. Until that time comes, ART should be used carefully in patients with BCa and UTUC on a case-by-case basis.",
keywords = "Adjuvant radiotherapy, Bladder cancer, Recurrence, Upper tract urothelial carcinoma",
author = "Takehiro Iwata and Shoji Kimura and Mohammad Abufaraj and Florian Janisch and Karakiewicz, {Pierre I.} and Veronika Seebacher and Morgan Roupr{\^e}t and Yasutomo Nasu and Shariat, {Shahrokh F.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.urolonc.2019.05.021",
language = "English",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma

T2 - A systematic review

AU - Iwata, Takehiro

AU - Kimura, Shoji

AU - Abufaraj, Mohammad

AU - Janisch, Florian

AU - Karakiewicz, Pierre I.

AU - Seebacher, Veronika

AU - Rouprêt, Morgan

AU - Nasu, Yasutomo

AU - Shariat, Shahrokh F.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objectives: The role of adjuvant radiotherapy (ART) in patients with bladder cancer (BCa) and upper tract urothelial carcinoma (UTUC) is controversial. We systematically evaluated the oncologic efficacy of ART and its associated toxicity in patients treated with surgery and ART for BCa and UTUC. Materials and method: We performed a literature search on December 2018 using MEDLINE, Web of Science, Cochrane databases and Scopus according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Fourteen BCa studies and 14 UTUC studies were included in this systematic review. The data were too scarce and heterogeneous for meta-analytical analysis. Results: The quality and quantity of the data on ART in BCa and UTUC patients are limited. The combination of ART and chemotherapy appears to be beneficial in patients with locally advanced BCa or UTUC. The early and late adverse effects of ART are decreasing reflecting the progress in radiation technology. Conclusions: According to the currently available literature, there is no clear benefit of ART after radical surgery in BCa and UTUC. Future efforts should focus on evaluating multimodal approach using ART with chemotherapy. Until that time comes, ART should be used carefully in patients with BCa and UTUC on a case-by-case basis.

AB - Objectives: The role of adjuvant radiotherapy (ART) in patients with bladder cancer (BCa) and upper tract urothelial carcinoma (UTUC) is controversial. We systematically evaluated the oncologic efficacy of ART and its associated toxicity in patients treated with surgery and ART for BCa and UTUC. Materials and method: We performed a literature search on December 2018 using MEDLINE, Web of Science, Cochrane databases and Scopus according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Fourteen BCa studies and 14 UTUC studies were included in this systematic review. The data were too scarce and heterogeneous for meta-analytical analysis. Results: The quality and quantity of the data on ART in BCa and UTUC patients are limited. The combination of ART and chemotherapy appears to be beneficial in patients with locally advanced BCa or UTUC. The early and late adverse effects of ART are decreasing reflecting the progress in radiation technology. Conclusions: According to the currently available literature, there is no clear benefit of ART after radical surgery in BCa and UTUC. Future efforts should focus on evaluating multimodal approach using ART with chemotherapy. Until that time comes, ART should be used carefully in patients with BCa and UTUC on a case-by-case basis.

KW - Adjuvant radiotherapy

KW - Bladder cancer

KW - Recurrence

KW - Upper tract urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85067988290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067988290&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2019.05.021

DO - 10.1016/j.urolonc.2019.05.021

M3 - Review article

C2 - 31255542

AN - SCOPUS:85067988290

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

ER -